再発または転移性の扁平上皮頭頚部がんに対するマルチキナーゼ阻害薬パゾパニブ+抗EGFR抗体セツキシマブ:オープンラベルの第Ⅰb相および拡大コホート試験【Lancet Oncology】

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

Lancet Oncology 2018年7月9日オンライン版

Summary

Background
Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metastatic HNSCC.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*